The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index; 1 of the 16 sources its claims cite were checked for support.
Improved endothelial function with metformin in type 2 diabetes mellitus
Open accessAbstract
Objectives This study was designed to assess the effect of metformin on impaired endothelial function in type 2 diabetes mellitus.Background Abnormalities in vascular endothelial function are well recognized among patients with type 2 (insulin-resistant) diabetes mellitus. Insulin resistance itself may be central to the pathogenesis of endothelial dysfunction. The effects of metformin, an antidiabetic agent that improves insulin sensitivity, on endothelial function have not been reported.Methods Subjects with diet-treated type 2 diabetes but without the confounding collection of cardiovascular risk factors seen in the metabolic syndrome were treated with metformin 500 mg twice daily (n = 29) or placebo (n = 15) for 12 weeks. Before and after treatment, blood flow responses to intraarterial administration of endothelium-dependent (acetylcholine), endothelium-independent (sodium nitroprusside) and nitrate-independent (verapamil) vasodilators were measured using forearm plethysmography. Whole-body insulin resistance was assessed on both occasions using the homeostasis model (HOMA-IR).Results Subjects who received metformin demonstrated statistically significant improvement in acetylcholine-stimulated flows compared with those treated with placebo (p = 0.0027 by 2-way analysis of variance), whereas no significant effect was seen on nitroprusside-stimulated (p = 0.27) or verapamil-stimulated (p = 0.40) flows. There was a significant improvement in insulin resistance with metformin (32.5% reduction in HOMA-IR, p = 0.01), and by stepwise multivariate analysis insulin resistance was the sole predictor of endothelium-dependent blood flow following treatment (r = -0.659, p = 0.0012).Conclusions Metformin treatment improved both insulin resistance and endothelial function, with a strong statistical link between these variables. This supports the concept of the central role of insulin resistance in the pathogenesis of endothelial dysfunction in type 2 diabetes mellitus. This has important implications for the investigation and treatment of vascular disease in patients with type 2 diabetes mellitus.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In diet-treated type 2 diabetes patients without the clustered metabolic syndrome risk factors, 12 weeks of metformin improved endothelium-dependent forearm blood flow and insulin resistance compared with placebo. Post-treatment insulin resistance was the sole predictor of endothelium-dependent vasodilation, supporting a central role for insulin resistance in endothelial dysfunction.
Key findings
- Metformin significantly improved acetylcholine-stimulated forearm blood flow versus placebo (p = 0.0027 by two-way ANOVA), while no significant treatment effect was seen for sodium nitroprusside (p = 0.27) or verapamil (p = 0.40).
- Metformin produced a 32.5% reduction in HOMA-IR (p = 0.01), with no change in the placebo group; FFA also changed significantly (p = 0.019).
- After treatment, stepwise multivariate analysis found insulin resistance (logHOMA-IR) was the sole predictor of endothelium-dependent blood flow (r = −0.659, adjusted r² = 0.434, p = 0.0012).
- Glucose, HbA1c, weight, blood pressure, and cholesterol did not show significant treatment-attributable changes.
Methods
- Randomized, placebo-controlled study of patients with diet-controlled type 2 diabetes without other major cardiovascular risk factors; participants received metformin 500 mg twice daily (n = 29) or placebo (n = 15) for 12 weeks, with 44 subjects initially enrolled and 4 withdrawals.
- Forearm strain-gauge plethysmography measured blood flow responses to intraarterial acetylcholine (endothelium-dependent), sodium nitroprusside (endothelium-independent), and verapamil (nitrate-independent); whole-body insulin resistance was assessed by HOMA-IR.
- Main analyses used two-way repeated-measures ANOVA, ANCOVA, linear regression, and forward stepwise regression.
Limitations
- The paper states that oxidative balance/oxidative stress and LDL particle size were not measured, though these variables affect endothelial function and may be affected by metformin.
- Evident from the text: the study was small, baseline LDL cholesterol was significantly lower in the placebo group, and FFA levels showed a borderline baseline difference favoring placebo.
- Evident from the text: pretreatment sodium nitroprusside responses unexpectedly differed between groups, and the direct correlation between change in insulin resistance and improvement in endothelial response did not reach statistical significance.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Own result · 10 Own method · 9 Not checked yet · 7 Own interpretation · 1 Supported so far · 1 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was a significant improvement in insulin resistance with metformin (32.5% reduction in HOMA-IR, p ϭ 0.01)”
- Also stated in: § Demographics. · plain
“Metformin produced a significant 32.5% drop in HOMA-IR, whereas no change was seen in the patients receiving placebo.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > RESULTS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Demographics. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The inclusion of these variables with the change in BMI and in lipid variables in a multivariate model accounted for Ͼ95% of the variation in the change in endothelial response (p ϭ 0.005).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Blood flow responses.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“by stepwise multivariate analysis insulin resistance was the sole predictor of endotheliumdependent blood flow following treatment (r ϭ Ϫ0.659, p ϭ 0.0012).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > RESULTS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After therapy with metformin, univariate ANOVA revealed an effect of logHOMA-IR (p ϭ 0.06) and of body mass index (BMI) (p ϭ 0.007) on endothelial responses.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Blood flow responses.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of note, no relationship with LDL cholesterol, ambient glucose, Hb A1c or FFA level was evident.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Blood flow responses.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas no significant effect was seen on nitroprusside-stimulated (p ϭ 0.27) or verapamil-stimulated (p ϭ 0.40) flows.”
- Also stated in: § Blood flow responses. · plain
“across all doses there was no statistically significant treatment effect relative to placebo (p ϭ 0.27).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > RESULTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Blood flow responses. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Metformin treatment resulted in statistically significant improvements only in HOMA-IR and FFA levels compared to placebo”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Verapamil-induced, nitrateindependent flows were not different between groups either before or after treatment (p ϭ 0.40, Fig. 3).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Blood flow responses.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the present study, the direct correlation between the change in IR and the improvement in endothelial response did not achieve statistical significance”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but the combination of changes in IR, lipids, FFAs and BMI was able to account for the vast majority of the change in endothelial response.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 13
- The quote only partly states this claim. 2
- It may state two separate claims as one. 14
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Also, in ex-vivo preparations of vascular smooth muscle, a direct vasodilating action of metformin has been reported, possibly due to altered calcium handling (35,37,38).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > DISCUSSION
What the sources say
- Not checked yetcites [35] Abbasi, 1998, Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin, Diabetes Care source
- Not checked yetcites [37] Bhalla, 1996, Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat, Am J Hypertens source
- Supportedcites [38] Dominguez, 1996, Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle, Endocrinology source
The Introduction reports that metformin attenuates contraction of isolated rat tail artery rings and describes this as evidence of direct effects on vascular tissue. The paper's calcium results and Discussion report an attenuated thrombin-induced calcium rise in cultured vascular smooth muscle cells and suggest that this may help explain reduced vascular contraction. The proposed calcium mechanism is appropriately qualified as possible. (LLM, conf=0.88)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Subjects who received metformin demonstrated statistically significant improvement in acetylcholine-stimulated flows compared with those treated with placebo (p ϭ 0.0027 by 2-way analysis of variance)”
- Also stated in: § DISCUSSION · plain
“In patients with IR and type 2 DM, three months of treatment with metformin improved endotheliumdependent vascular responses, whereas vascular responses of patients treated with placebo remained unchanged.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > RESULTS
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Also stated in: § DISCUSSION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“without significant changes in body mass index, blood pressure or cholesterol levels.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment effects on glucose (0.5 mmol/l reduction) and weight (1.5 kg) were small and did not achieve statistical significance.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Demographics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the change in response at peak dose was statistically significant for metformin-treated subjects compared with their baseline (p ϭ 0.01), across all doses there was no statistically significant treatment effect relative to placebo (p ϭ 0.27).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Blood flow responses.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, univariate ANOVA revealed no effect of any metabolic or anthropomorphic parameters on endothelial responses, and similarly by ANCOVA there were no significant interactions of these effects on baseline responses.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Blood flow responses.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Following therapy, linear regression analyses revealed dependencies of endothelium-dependent responses following therapy on BMI (r ϭ Ϫ0.43, p ϭ 0.007), logHOMA-IR (r ϭ Ϫ0.486, p ϭ 0.017) (Fig. 4) and high density lipoprotein cholesterol (r ϭ 0.34, p ϭ 0.036).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Blood flow responses.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline endothelium-independent nitrate responses were unexpectedly higher in the group who received placebo, but at the end of treatment this difference was abolished (Fig. 2).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Blood flow responses.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Abnormalities in endothelium-dependent vascular responses, perhaps the earliest demonstrable alteration in vascular health, have been found among patients with type 2 DM (2,3).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > RESULTS
What the sources say
- Not checked yetcites [2] McVeigh, 1992, Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia source
- Not checked yetcites [3] Williams, 1996, Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus, J Am Coll Cardiol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Medication compliance was Ͼ95% by pill count.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Demographics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This trial was designed and performed in accordance with the principles of the Declaration of Helsinki and was approved by our University's Ethical Review Board.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Patients.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We did not undertake any measure of oxidative balance or oxidative stress, nor was LDL particle size measured.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Study limitations.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Written informed consent was obtained after the purpose, nature and potential risks of the interventions were explained to the subjects.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Patients.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“In fact, metformin has recently been reported to have antioxidant effects (34) in addition to the known favorable effects on circulating lipids (10) and FFAs (35).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > DISCUSSION
What the sources say
- Not checked yetcites [34] Faure, 1999, An insulin sensitizer improves the free radical defence system potential and insulin sensitivity in high fructose-fed rats, Diabetes source
- Not checked yetcites [10] Bailey, 1996, Metformin, N Engl J Med source
- Not checked yetcites [35] Abbasi, 1998, Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin, Diabetes Care source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“End point measures including blood flow data analyses were blinded to patient name, treatment assignment and treatment timing.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Patients.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Insulin resistance is felt to be central to the pathogenesis of the metabolic syndrome (Syndrome X), a clustering of traditional cardiovascular risk factors in patients with type 2 DM (8).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > RESULTS
What the sources say
- Not checked yetcites [8] Reaven, 1988, Role of insulin resistance in human disease, Diabetes source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Subjects assigned to metformin and placebo were well matched for degree of obesity and level of glycemic control, and both the fasting insulin level and the calculated index of IR indicated equivalent degrees of IR.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Demographics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Four subjects withdrew from the study before the second set of measurements, two of whom had been assigned to receive metformin therapy.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Demographics.
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Flow data analysis was performed at a later date by investigators blind to patient name, study day and treatment assignment.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Vascular responses.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The level of low density lipoprotein (LDL) cholesterol was significantly lower in the group who received placebo.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Demographics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Again, ANCOVA revealed no interactions, suggesting that the chance imbalances between groups, particularly with regard to LDL cholesterol, did not influence the results.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Blood flow responses.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Metformin treatment improved both insulin resistance and endothelial function, with a strong statistical link between these variables.”
- Also stated in: § Conclusions. · plain
“In our group of patients with type 2 DM and IR but without other metabolic abnormalities, we found that treatment with metformin resulted in improved IR and improved endothelial function.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > RESULTS
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
- Also stated in: § Conclusions. · plain
In the paper
“Despite a clear improvement in insulin sensitivity with treatment, no improvement in insulin-mediated or agonist-stimulated vasodilation was seen.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > DISCUSSION
What the sources say
- Not checked yetcites [32] Tack, 1998, Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone, Diabetologia source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A direct metformin effect in vascular endothelial cells is also possible, and supported by recent findings in insulin-resistant rats (36).”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > DISCUSSION
What the sources say
- Not checked yetcites [36] Katakam, 2000, Metformin improves vascular function in insulin-resistant rats, Hypertension source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, an important effect of IR per se on endothelial function is suggested by the fact that a relationship was not evident at baseline but was brought out by metformin therapy, which concurrently improved insulin sensitivity and endothelial function.”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The effects of altering insulin resistance with metformin on endothelial function in humans have not been previously reported.
“The effects of altering IR with metformin on endothelial function in humans have not been previously reported.”
“The effects of metformin, an antidiabetic agent that improves insulin sensitivity, on endothelial function have not been reported.”
The paper relies on this without support.
No evidence links alterations in antioxidant, lipid, or FFA parameters with improvements in vascular function separate from improvements in insulin resistance.
“However, no evidence links alterations in these parameters with improvements in vas-cular function separate from improvements in IR, and therefore the hypothesis of the central role of IR remains plausible.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mather et al. reported that compared to placebo, metformin improved endothelium-dependent, but not endothelium-independent vasodilation thus highlighting the primary dysfunction in blood flow was not the vascular smooth muscle response but was secondary to endothelial dysfunction (106).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [106]
In the citing paper
“Based on critical reviews of the literature, the answer appears to be “yes”, although the clinical data could be interpreted as secondary to metformin’s actions to enhance insulin sensitivity and lower blood glucose levels (34, 106, 173).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [106]
In the citing paper
“Mather et al. reported that metformin has no effect on endothelium dependent blood flow but has a significant effect on endothelium independent blood flow and insulin resistance reduction [89].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [89]
In the citing paper
“Many different mechanisms, beyond glycemic control, have been implicated in vascular protection induced by metformin such as improvements in the inflammatory pathway [86], coagulation [87], oxidative stress and glycation [88-92], endothelial dysfunction [88-90], haemostasis [88,91-93], insulin resistance improvement [94], lipid profiles [95,96], and fat redistribution [97,98].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Parameter | (n ؍ 15) | (n ؍ 28) | | Age (yrs) | 54.8 (2.6) | 50.7 (1.8) | | Gender (M/F) | 11/4 | 15/14 |”
§ Endothelial Function Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus > Conclusions.
Reported 28 · recomputed 29
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Self-citationBonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Steinberg, H. O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G., & Baron, A. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118709 · Cited by 1,687
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
Williams, S. B., Cusco, J. A., Roddy, M.-A., Johnstone, M. T., & Creager, M. A. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00522-6 · Cited by 1,014
McVeigh, G. E., Brennan, G. M., Johnston, G. D., McDermott, B. J., McGrath, L. T., Henry, W. R., Andrews, J. W., & Hayes, J. R. (1992) · Diabetologia · doi:10.1007/bf00429099 · Cited by 916
Research works printed but not linked: 1
- Paradisi, 1999, Troglitazone therapy improves endothelial function in women with polycystic ovary syndrome, Diabetes, 48, A129
Cited by
Sorted by citations
The clinical implications of endothelial dysfunction
Widlansky, M. E., Gokce, N., Keaney, J. F., & Vita, J. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00994-x · Cited by 1,749
Creager, M. A., Lüscher, T. F., of, P. W. T. A., Cosentino, F., & Beckman, J. A. (2003) · Circulation · doi:10.1161/01.cir.0000091257.27563.32 · Cited by 1,675
Kim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,393
The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome
Zhang, J., Bottiglieri, T., & McCullough, P. A. (2016) · Cardiorenal Medicine · doi:10.1159/000452283 · Cited by 1,084
Oral Antihyperglycemic Therapy for Type 2 Diabetes
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Cardiovascular Actions of Insulin
Muniyappa, R., Montagnani, M., Koh, K. K., & Quon, M. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0006 · Cited by 888
Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome.
Hadi, H. A. R., Carr, C. S., & Suwaidi, J. M. S. A. (2005) · PubMed Central · Cited by 807
Kolluru, G. K., Bir, S. C., & Kevil, C. G. (2012) · International Journal of Vascular Medicine · doi:10.1155/2012/918267 · Cited by 752
Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 690
Resistin Promotes Endothelial Cell Activation
Verma, S., Li, S., Wang, C., Fedak, P. W. M., Li, R., Weisel, R. D., & Mickle, D. A. G. (2003) · Circulation · doi:10.1161/01.cir.0000084503.91330.49 · Cited by 670
Self-citationBiomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus
Meigs, J. B. (2004) · JAMA · doi:10.1001/jama.291.16.1978 · Cited by 643
Fundamentals of Endothelial Function for the Clinical Cardiologist
Verma, S., & Anderson, T. J. (2002) · Circulation · doi:10.1161/hc0502.104540 · Cited by 614
Self-citationEndothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications
Tabit, C. E., Chung, W. B., Hamburg, N. M., & Vita, J. A. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9134-4 · Cited by 594
Endothelial dysfunction in diabetes mellitus.
Hadi, H. A. R., & Suwaidi, J. M. S. A. (2007) · Europe PMC (PubMed Central) · Cited by 568
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Endothelial Function Testing as a Biomarker of Vascular Disease
Verma, S., Buchanan, M. R., & Anderson, T. J. (2003) · Circulation · doi:10.1161/01.cir.0000089191.72957.ed · Cited by 575
Self-citationInsulin resistance and endothelial dysfunction: the road map to cardiovascular diseases
Cersósimo, E., & DeFronzo, R. A. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.634 · Cited by 531
Mitochondria and Endothelial Function
Kluge, M. A., Fetterman, J. L., & Vita, J. A. (2013) · Circulation Research · doi:10.1161/circresaha.111.300233 · Cited by 508
The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction
An, Y., Xu, B.-T., Wan, S., Xiu-mei, M., Long, Y., Xu, Y., & Jiang, Z. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01965-7 · Cited by 462
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 447
Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease
Caballero, A. E. (2003) · Obesity Research · doi:10.1038/oby.2003.174 · Cited by 416
Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0719 · Cited by 366
Endothelial dysfunction and cardiovascular disease
Widmer, R. J., & Lerman, A. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.43 · Cited by 362
Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction
Xu, J., & Zou, M. (2009) · Circulation · doi:10.1161/circulationaha.108.835223 · Cited by 360
Diabetes and pancreatic cancer
Li, D. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20771 · Cited by 318
Hundal, R. S., & Inzucchi, S. E. (2003) · Drugs · doi:10.2165/00003495-200363180-00001 · Cited by 315
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.21.2594 · Cited by 312
Pathophysiological implications of insulin resistance on vascular endothelial function
Wheatcroft, S. B., Williams, I. L., Shah, A. M., & Kearney, M. T. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00869.x · Cited by 316
Metformin monotherapy for type 2 diabetes mellitus
Sáenz, A., Fernandez-Esteban, I., Mataix, A. L., Segura, M. A., Figuls, M. R. I., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 310
RetractedActivation and Signaling by the AMP-Activated Protein Kinase in Endothelial Cells
Fisslthaler, B., & Fleming, I. (2009) · Circulation Research · doi:10.1161/circresaha.109.201590 · Cited by 295
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 310
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R. S., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 300
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
Diamanti‐Kandarakis, E., Paterakis, T., Alexandraki, K., Piperi, C., Aessopos, A., Katsikis, I., Katsilambros, N. L., Kreatsas, G., & Panidis, D. (2006) · Human Reproduction · doi:10.1093/humrep/del003 · Cited by 262
Keske, M. A., Montagnani, M., & Quon, M. J. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0018-9 · Cited by 232
Brownfoot, F. C., Hastie, R., Hannan, N. J., Cannon, P., Tuohey, L., Parry, L. J., Senadheera, S., Illanes, S. E., Kaitu’u-Lino, T. J., & Tong, S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.019 · Cited by 222
Metformin modulates hyperglycaemia‐induced endothelial senescence and apoptosis through SIRT1
Arunachalam, G., Samuel, S. M., Marei, I., Ding, H., & Triggle, C. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12496 · Cited by 221
de Jager, J., Kooy, A., Lehert, P., Bets, D., Wulffelé, M. G., Teerlink, T., Scheffer, P. G., Schalkwijk, C., Donker, A. J. M., & Stehouwer, C. D. A. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01420.x · Cited by 222
The endothelium: influencing vascular smooth muscle in many ways
Triggle, C. R., Samuel, S. M., Ravishankar, S., Marei, I., Arunachalam, G., & Ding, H. (2012) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y2012-073 · Cited by 229
An Integrated View of Insulin Resistance and Endothelial Dysfunction
Muniyappa, R., Iantorno, M., & Quon, M. J. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.06.001 · Cited by 227
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211
Golay, A. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803695 · Cited by 206
Apostolova, N., Iannantuoni, F., Gruevska, A., Muntané, J., Rocha, M., & Víctor, V. M. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101517 · Cited by 208
Natali, A., Toschi, E., Baldeweg, S. E., Ciociaro, D., Favilla, S., Saccà, L., & Ferrannini, E. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1076 · Cited by 200
Woodman, R. J., Mori, T. A., Burke, V., Puddey, I. B., Barden, A. E., Watts, G. F., & Beilin, L. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00307-6 · Cited by 198
Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction
Maruhashi, T., & Higashi, Y. (2021) · Antioxidants · doi:10.3390/antiox10081306 · Cited by 203
Coenzyme Q10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus
Watts, G. F., Playford, D. A., Croft, K. D., Ward, N. C., Mori, T. A., & Burke, V. (2002) · Diabetologia · doi:10.1007/s00125-001-0760-y · Cited by 193
Setter, S. M., Iltz, J. L., Thams, J., & Campbell, R. K. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90089-0 · Cited by 193
Goldberg, R. B., Orchard, T. J., Crandall, J. P., Boyko, E. J., Budoff, M. J., Dabelea, D., Gadde, K. M., Knowler, W. C., Lee, C. G., Nathan, D. M., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056756 · Cited by 191
Hemostatic Markers of Endothelial Dysfunction and Risk of Incident Type 2 Diabetes
Meigs, J. B., O’Donnell, C. J., Tofler, G. H., Benjamin, E. J., Fox, C. S., Lipinska, I., Nathan, D. M., SULLIVAN, L. M., D’Agostino, R. B., & Wilson, P. W. F. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1041 · Cited by 184
Mohan, M., Al-Talabany, S., McKinnie, A., Mordi, I. R., Singh, J. S., Gandy, S. J., Baig, F., Hussain, M. S., Bhalraam, U., Khan, F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz203 · Cited by 184
Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes
Natali, A., Baldeweg, S. E., Toschi, E., Capaldo, B., Barbaro, D., Gastaldelli, A., Yudkin, J. S., & Ferrannini, E. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1349 · Cited by 180
Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk
Anderson, T. J. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70990-4 · Cited by 178
Self-citationKröller‐Schön, S., Knorr, M., Hausding, M., Oelze, M. W., Schuff, A., Schell, R., Sudowe, S., Scholz, A., Daub, S., Karbach, S. H., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs246 · Cited by 177
Fernandes, R., Viana, S., Nunes, S., & Reis, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.09.032 · Cited by 171
Metformin restores endothelial function in aorta of diabetic rats
Sena, C. M., Matafome, P. N., Louro, T. M., Nunes, E., Fernandes, R., & Seiça, R. M. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01230.x · Cited by 168
Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome
Reusch, J. E. B. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02555-9 · Cited by 167
Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
Fonseca, V. A., Desouza, C. V., Asnani, S., & Jialal, I. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0034 · Cited by 169
Metformin improves endothelial function in patients with metabolic syndrome
VITALE, C., MERCURO, G., CORNOLDI, A., FINI, M., VOLTERRANI, M., & ROSANO, G. M. C. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01531.x · Cited by 164
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2006) · The Cochrane Database of Systematic Reviews (Complete Reviews) · doi:10.1002/14651858.cd002967.pub2 · Cited by 163
Johnson, J. A., Simpson, S. H., Toth, E. L., & Majumdar, S. R. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01448.x · Cited by 161
Type 2 Diabetic Individuals Have Impaired Leg Blood Flow Responses to Exercise
Kingwell, B. A., Formosa, M. F., Muhlmann, M. H., Bradley, S. J., & McConell, G. K. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.899 · Cited by 161
Goodarzi, M. O., & Bryer‐Ash, M. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00448.x · Cited by 163
Abbasi, F., Chu, J. W., McLaughlin, T., Lamendola, C. A., Leary, E. T., & Reaven, G. M. (2004) · Metabolism · doi:10.1016/j.metabol.2003.07.020 · Cited by 162
Jadhav, S., Ferrell, W., Greer, I. A., Petrie, J. R., Cobbe, S. M., & Sattar, N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.088 · Cited by 157
Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction
Anderson, T. J. (2003) · Heart Failure Reviews · doi:10.1023/a:1022199021949 · Cited by 158
Self-citationNiu, C., Chen, Z., Kim, K., Sun, J. M., Xue, M., Chen, G., Li, S., Shen, Y., Zhu, Z., Wang, X., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1569913 · Cited by 154
Marchesini, G., Forlani, G., Cerrelli, F., Manini, R., Natale, S., Baraldi, L., Ermini, G., Savorani, G., Zocchi, D., & Melchionda, N. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01115.x · Cited by 152
Caballero, A. E., Delgado, A., Aguilar-Salinas, C. A., Herrera, A. N., Castillo, J. L., Cabrera, T., Gomez-Perez, F. J., & Rull, J. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0019 · Cited by 151
Teodoro, J. S., Nunes, S., Rolo, A. P., Reis, F., & Palmeira, C. M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01857 · Cited by 150
Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.133 · Cited by 142
Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes
Bailey, C. J. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6092-0 · Cited by 138
Goldberg, R. B., Aroda, V. R., Bluemke, D. A., Barrett-Connor, E. L., Budoff, M. J., Crandall, J. P., Dabelea, D., Horton, E. S., Mather, K. J., Orchard, T. J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025483 · Cited by 141
Self-citationThe cardioprotective effects of metformin
Messaoudi, S. E., Rongen, G. A. P. J. M., de Boer, R. A., & Riksen, N. P. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834ae1a7 · Cited by 131
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 143
de Jager, J., Kooy, A., Schalkwijk, C., van der Kolk, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J., & Stehouwer, C. D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12128 · Cited by 129
Endothelial Function and Dysfunction: Impact of Metformin
Nafisa, A., Gray, S. G., Cao, Y., Wang, T., Xu, S., Wattoo, F. H., Barras, M., Cohen, N., Kamato, D., & Little, P. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.07.007 · Cited by 128
Surrogate measures of insulin resistance: of rats, mice, and men
Mather, K. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90889.2008 · Cited by 127
Self-citationWang, C., Ting, M., Verma, S., Kuo, L., Yang, N., Hsieh, C., Wang, S.-Y., Hung, A., & Cherng, W. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.07.029 · Cited by 127
Self-citationMatsumoto, T., Noguchi, E., Ishida, K., Kobayashi, T., Yamada, N., & Kamata, K. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00486.2008 · Cited by 125
Vascular Oxidative Stress: The Common Link in Hypertensive and Diabetic Vascular Disease
Cohen, R. A., & Tong, X. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181d89670 · Cited by 129
Davies, J. I., Band, M. M., Morris, A. D., & Struthers, A. D. (2004) · Diabetologia · doi:10.1007/s00125-004-1510-8 · Cited by 126
Cohen, N. D., Dunstan, D. W., Robinson, C., Vulikh, E., Zimmet, P. Z., & Shaw, J. E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.020 · Cited by 122
The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients
Ersoy, C., Kiyici, S. K., Budak, F., Oral, H. B., Güçlü, M., Duran, C., Selimoğlu, H., Ertürk, E., Tuncel, E., & İmamoğlu, Ş. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.02.006 · Cited by 127
Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function
Ding, Y., Zhou, Y., Ling, P., Feng, X., Luo, S., Zheng, X., Little, P. J., Xu, S., & Weng, J. (2021) · Theranostics · doi:10.7150/thno.64706 · Cited by 121
The importance of insulin resistance in polycystic ovary syndrome
Goodarzi, M. O., & Korenman, S. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00734-9 · Cited by 118
Ding, H., & Triggle, C. R. (2005) · Vascular Health and Risk Management · doi:10.2147/vhrm.1.1.55.58939 · Cited by 118
Kraemer‐Aguiar, L. G., Bahia, L. R., Villela, N., Laflor, C., Sicuro, F., Wiernsperger, N., Bottino, D., & Bouskela, E. (2006) · Diabetes Care · doi:10.2337/diacare.2951083 · Cited by 119
Endothelial dysfunction in type 2 diabetes mellitus
Avogaro, A., Fadini, G. P., Gallo, A., Pagnin, E., & de Kreutzenberg, S. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.10.015 · Cited by 116
Majithiya, J. B., & Balaraman, R. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.10.020 · Cited by 114
Durham, A. E., Rendle, D. I., & Newton, J. R. (2008) · Equine Veterinary Journal · doi:10.2746/042516408x273648 · Cited by 117
Goel, S. K., Singh, R. P., Singh, V., Singh, H., Kumari, P., Chopra, H., Sharma, R., Nepovimová, E., Vališ, M., Kuča, K., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1022739 · Cited by 113
Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA
Sydow, K., Mondon, C. E., & Cooke, J. P. (2005) · Vascular Medicine · doi:10.1177/1358836x0501000106 · Cited by 114
Role of Heme in Cardiovascular Physiology and Disease
Sawicki, K. T., Chang, H., & Ardehali, H. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001138 · Cited by 112
Reversibility of endothelial dysfunction in diabetes: role of polyphenols
Suganya, N., Bhakkiyalakshmi, E., Sarada, D. V. L., & Ramkumar, K. M. (2016) · British Journal Of Nutrition · doi:10.1017/s0007114516001884 · Cited by 116
Resistin, acute coronary syndrome and prognosis results from the AtheroGene study
Lubos, E., Messow, C., Schnabel, R. B., Rupprecht, H. J., Espinola–Klein, C., Bickel, C., Peetz, D., Post, F., Lackner, K. J., Tiret, L., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.039 · Cited by 109
Nuver, J., Smit, A. J., Postma, A., Sleijfer, D. T., & Gietema, J. A. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00038-5 · Cited by 105
Metadata
- Authors
- Mather, K. J., Verma, S., & Anderson, T. J.
- Affiliations
- Indiana University Indianapolis (US)
- University of Toronto (CA)
- University of Calgary (CA)
- Corresponding author
- Anderson, Todd J
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2001-04
- Volume
- 37
- Issue
- 5
- Pages
- 1344-1350
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2114391822
- Cited by
- 513
- References
- 47
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 15 · 2023: 10 · 2022: 15 · 2021: 17 · 2020: 19 · 2019: 18 · 2018: 18 · 2017: 27 · 2016: 13 · 2015: 23 · 2014: 20 · 2013: 25 · 2012: 25
- FWCI
- 17.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- Alberta Heritage Foundation for Medical Research
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- metformin, endothelial dysfunction, type 2 diabetes, insulin resistance, acetylcholine-induced vasodilation, forearm blood flow, HOMA-IR, insulin-sensitizing drugs, vascular disease
- MeSH terms
- Blood Flow Velocity, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Endothelium, Vascular, Female, Forearm, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Plethysmography, Vasodilation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
